Anemia is associated with an elevated serum level of high-molecular-weight adiponectin in patients with type 2 diabetes independently of renal dysfunction

Translational Research

Volumn 154, Issue 4, 2009, Pages 175-182

  Aso, Yoshimasa ^a   Suganuma, Ruriko ^a   Wakabayashi, Sadao ^a   Hara, Kenji ^a   Nakano, Tomoki ^a   Suetsugu, Mariko ^a   Matsumoto, Sachiko ^a   Nakamachi, Takafumi ^a   Takebayashi, Kohzo ^a   Morita, Kimio ^a   Inukai, Toshihiko ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALBUMIN; C REACTIVE PROTEIN; ERYTHROPOIETIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH MOLECULAR WEIGHT ADIPONECTIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ARTICLE; BODY MASS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GLOMERULUS FILTRATION RATE; HEMATOCRIT; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEINURIA;

EID: 70249098457     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2009.07.005     Document Type: Article

References (40)

1. Berg A.H., Combs T.P., Du X., Brownlee M., and Scherer P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7 (2001) 947-953
2. Yamauchi T., Kamon J., Waki H., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7 (2001) 941-946
3. Ouchi N., Kihara S., Arita Y., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103 (2001) 1057-1063
4. Ouchi N., Kihara S., Arita Y., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102 (2000) 1296-1301
5. Pajvani U.B., Du X., Combs T.P., et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 278 (2003) 9073-9085
6. Tsao T.S., Tomas E., Murrey H.E., et al. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J Biol Chem 278 (2003) 50810-50817
7. Pajvani U.B., Hawkins M., Combs T.P., et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279 (2004) 12152-12162
8. Hotta K., Funahashi T., Arita Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 (2000) 1595-1599
9. Kumada M., Kihara S., Sumitsuji S., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23 (2003) 85-89
10. Aso Y., Yamamoto R., Wakabayashi S., et al. Comparison of serum high-molecular-weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 55 (2006) 1954-1960
11. Lindsay R.S., Funahashi T., Hanson R.L., et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360 (2002) 57-58
12. Pischon T., Girman C.J., Hotamisligil G.S., Rifai N., Hu F.B., and Rimm E.B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (2004) 1730-1737
13. Zoccali C., Mallamaci F., Tripepi G., et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13 (2002) 134-141
14. Wakabayashi S., and Aso Y. Adiponectin concentrations in sera from patients with type 2 diabetes are negatively associated with sympathovagal balance as evaluated by power spectral analysis of heart rate variation. Diabetes Care 27 (2004) 2392-2397
15. Adamczak M., Rzepka E., Chudek J., and Wiecek A. Ageing and plasma adiponectin concentration in apparently healthy males and females. Clin Endocrinol 62 (2005) 114-118
16. Saraheimo M., Forsblom C., Fagerudd J., et al. Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care 28 (2005) 1410-1414
17. Koshimura J., Fujita H., Narita T., et al. Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy. Biochem Biophys Res Commun 316 (2004) 165-169
18. Hsu C.Y., McCulloch C.E., and Curhan G.C. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 13 (2002) 504-510
19. Vlagopoulos P.T., Tighiouart H., Weiner D.E., et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol 16 (2005) 3403-3410
20. Astor B.C., Muntner P., Levin A., Eustace J.A., and Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 162 (2002) 1401-1408
21. Craig K.J., Williams J.D., Riley S.G., et al. Anemia and diabetes in the absence of nephropathy. Diabetes Care 28 (2005) 1118-1123
22. Al-Khoury S., Afzali B., Shah N., Covic A., Thomas S., and Goldsmith D.J. Anaemia in diabetic patients with chronic kidney disease-prevalence and predictors. Diabetologia 49 (2006) 1183-1189
23. Reinecke H., Trey T., Wellmann J., et al. Haemoglobin-related mortality in patients undergoing percutaneous coronary interventions. Eur Heart J 24 (2003) 2142-2150
24. Al-Ahmad A., Rand W.M., Manjunath G., et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38 (2001) 955-962
25. Kistorp C., Faber J., Galatius S., et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112 (2005) 1756-1762
26. Menon V., Li L., Wang X., et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 17 (2006) 2599-2606
27. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
28. World Health Organisation. Nutritional anemia: Report of a WHO Scientific Group (1968), World Health Organisation, Geneva, Switzerland
29. Hirose H., Kawai T., Yamamoto Y., et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 51 (2002) 314-317
30. Aso Y., Yamamoto R., Suetusgu M., et al. Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with type 2 diabetes. Diabet Med 24 (2007) 962-968
31. Nakano Y., Tajima S., Yoshimi A., et al. A novel enzyme-linked immunosorbent assay specific for high-molecular-weight adiponectin. J Lipid Res 47 (2006) 1572-1582
32. Matsubara M., Namioka K., and Katayose S. Relationships between plasma adiponectin and blood cells, hepatopancreatic enzymes in women. Thromb Haemost 91 (2004) 360-366
33. Maiese K., Li F., and Chong Z.Z. New avenues of exploration for erythropoietin. JAMA 293 (2005) 90-95
34. Natarajan R., Salloum F.N., Fisher B.J., Kukreja R.C., and Fowler III A.A. Hypoxia inducible factor-1 upregulates adiponectin in diabetic mouse hearts and attenuates post-ischemic injury. J Cardiovasc Pharmacol 51 (2008) 178-187
35. Eckardt K.U., and Kurtz A. Regulation of erythropoietin production. Eur J Clin Invest 35 (2005) 13-19
36. Hosogai N., Fukuhara A., Oshima K., et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 56 (2007) 901-911
37. Cavusoglu E., Ruwende C., Chopra V., et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J 27 (2006) 2300-2309
38. McFarlane S.I., Salifu M.O., Makaryus J., and Sowers J.R. Anemia and cardiovascular disease in diabetic nephropathy. Curr Diab Rep 6 (2006) 213-218
39. von Eynatten M., Hamann A., Twardella D., Nawroth P.P., Brenner H., and Rothenbacher D. Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. Eur Heart J 29 (2008) 1307-1315
40. Krzyzanowska K., Aso Y., Mittermayer F., Inukai T., Brix J., and Schernthaner G. High-molecular-weight adiponectin does not predict cardiovascular events in patients with type 2 diabetes. Transl Res 153 (2009) 199-203